CHIME - A tailored HCV microelimination project in Viennese people who inject drugs at drug centralized substitution centers

IF 3.5 4区 医学 Q2 IMMUNOLOGY Journal of Virus Eradication Pub Date : 2023-09-01 DOI:10.1016/j.jve.2023.100338
Caroline Schwarz , Raphael Schubert , Michael Schwarz , Angelika Schütz , Anika Jenke , David Bauer , Benjamin Steinwender , Enisa Gutic , Thomas Reiberger , Hans Haltmayer , Michael Gschwantler
{"title":"CHIME - A tailored HCV microelimination project in Viennese people who inject drugs at drug centralized substitution centers","authors":"Caroline Schwarz ,&nbsp;Raphael Schubert ,&nbsp;Michael Schwarz ,&nbsp;Angelika Schütz ,&nbsp;Anika Jenke ,&nbsp;David Bauer ,&nbsp;Benjamin Steinwender ,&nbsp;Enisa Gutic ,&nbsp;Thomas Reiberger ,&nbsp;Hans Haltmayer ,&nbsp;Michael Gschwantler","doi":"10.1016/j.jve.2023.100338","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Hepatitis C remains highly prevalent among people who inject drugs (PWIDs). We propose an integrated approach for screening/diagnostic testing and treatment in 6,665 Viennese PWIDs registered to access opioid agonist therapy (OAT).</p></div><div><h3>Methods</h3><p>OAT prescriptions were required monthly at one of nine approved authorities, making them ideal platforms for hepatitis C virus (HCV) screening. All PWIDs attending these authorities between January 2019 and March 2020 were offered on-site HCV screening, and consecutive HCV RNA PCR in case of positive HCV serology. In HCV viremic PWIDs, offsite referral to HCV care and treatment according to directly observed therapy (DOT) alongside OAT were performed.</p></div><div><h3>Results</h3><p>4,327/6,665 (64.9%) individuals were contacted before the COVID-19-related project discontinuation. There were 1,538/4,327 (35.5%) individuals who had participated in the study. HCV serology was available in 1,510/1,538 (98.2%): 795/1,519 (52.6%) had a positive serology, among whom 632 (79.5%) were followed-up with a PCR test. In 8/1,538 (0.5%) additional study participants HCV RNA PCR was assessed without prior serological screening. 239/640 (37.3%) individuals were HCV viremic with 51 (21.3%) having started on direct-acting antivirals (DAAs). 48/51 (94.1%) had completed treatment, among whom 42 (87.5% according to ITT) had achieved sustained virologic response at 12 weeks after completing treatment (SVR12) and 6 (12.5%) had been lost to follow-up after completion of therapy (SVR12 according to mITT: 42/42, 100%). No treatment failures had occurred.</p></div><div><h3>Conclusion</h3><p>Providing integrated point-of-care HCV screening/diagnostic testing at central OAT approved centers, followed by DOT with DAAs, represents an effective HCV microelimination strategy. While some PWIDs were lost in the cascade to cure and the absolute number of SVR was limited by the COVID-19 pandemic, our approach will allow linkage to care in a large proportion of Viennese PWIDs.</p></div>","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"9 3","pages":"Article 100338"},"PeriodicalIF":3.5000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f4/25/main.PMC10474458.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Virus Eradication","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2055664023000249","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Hepatitis C remains highly prevalent among people who inject drugs (PWIDs). We propose an integrated approach for screening/diagnostic testing and treatment in 6,665 Viennese PWIDs registered to access opioid agonist therapy (OAT).

Methods

OAT prescriptions were required monthly at one of nine approved authorities, making them ideal platforms for hepatitis C virus (HCV) screening. All PWIDs attending these authorities between January 2019 and March 2020 were offered on-site HCV screening, and consecutive HCV RNA PCR in case of positive HCV serology. In HCV viremic PWIDs, offsite referral to HCV care and treatment according to directly observed therapy (DOT) alongside OAT were performed.

Results

4,327/6,665 (64.9%) individuals were contacted before the COVID-19-related project discontinuation. There were 1,538/4,327 (35.5%) individuals who had participated in the study. HCV serology was available in 1,510/1,538 (98.2%): 795/1,519 (52.6%) had a positive serology, among whom 632 (79.5%) were followed-up with a PCR test. In 8/1,538 (0.5%) additional study participants HCV RNA PCR was assessed without prior serological screening. 239/640 (37.3%) individuals were HCV viremic with 51 (21.3%) having started on direct-acting antivirals (DAAs). 48/51 (94.1%) had completed treatment, among whom 42 (87.5% according to ITT) had achieved sustained virologic response at 12 weeks after completing treatment (SVR12) and 6 (12.5%) had been lost to follow-up after completion of therapy (SVR12 according to mITT: 42/42, 100%). No treatment failures had occurred.

Conclusion

Providing integrated point-of-care HCV screening/diagnostic testing at central OAT approved centers, followed by DOT with DAAs, represents an effective HCV microelimination strategy. While some PWIDs were lost in the cascade to cure and the absolute number of SVR was limited by the COVID-19 pandemic, our approach will allow linkage to care in a large proportion of Viennese PWIDs.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
CHIME -在维也纳药物集中替代中心注射毒品的人群中量身定制的HCV微消除项目
背景丙型肝炎在注射毒品的人群中仍然非常普遍。我们提出了一种对6665名注册接受阿片类激动剂治疗(OAT)的维也纳PWID进行筛查/诊断测试和治疗的综合方法。2019年1月至2020年3月期间,所有参加这些机构的PWID都接受了现场HCV筛查,并在HCV血清学阳性的情况下进行了连续的HCV RNA PCR。在HCV病毒血症PWID中,根据直接观察治疗(DOT)和OAT进行场外转诊至HCV护理和治疗。结果4327/6665(64.9%)人在COVID-19相关项目停止前接触过。共有1538/4327人(35.5%)参与了这项研究。1510/1538(98.2%)有HCV血清学可用:795/1519(52.6%)有阳性血清学,其中632(79.5%)接受了PCR检测。在8/1538(0.5%)的额外研究参与者中,在没有进行血清学筛查的情况下对HCV RNA PCR进行了评估。239/640人(37.3%)患有丙型肝炎病毒血症,其中51人(21.3%)已开始服用直接作用抗病毒药物(DAAs)。48/51(94.1%)已完成治疗,其中42人(根据ITT,87.5%)在完成治疗后12周达到持续的病毒学应答(SVR12),6人(12.5%)在治疗结束后失去随访(根据mITT,SVR12:42/42,100%)。未发生任何治疗失败。结论在OAT批准的中心提供综合护理点HCV筛查/诊断测试,然后提供DOT和DAAs,是一种有效的HCV微清除策略。虽然一些PWID在级联治疗中丢失,并且SVR的绝对数量受到新冠肺炎大流行的限制,但我们的方法将允许在很大一部分维也纳PWID中进行护理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Virus Eradication
Journal of Virus Eradication Medicine-Public Health, Environmental and Occupational Health
CiteScore
6.10
自引率
1.80%
发文量
28
审稿时长
39 weeks
期刊介绍: The Journal of Virus Eradication aims to provide a specialist, open-access forum to publish work in the rapidly developing field of virus eradication. The Journal covers all human viruses, in the context of new therapeutic strategies, as well as societal eradication of viral infections with preventive interventions. The Journal is aimed at the international community involved in the prevention and management of viral infections. It provides an academic forum for the publication of original research into viral reservoirs, viral persistence and virus eradication and ultimately development of cures. The Journal not only publishes original research, but provides an opportunity for opinions, reviews, case studies and comments on the published literature. It focusses on evidence-based medicine as the major thrust in the successful management of viral infections.The Journal encompasses virological, immunological, epidemiological, modelling, pharmacological, pre-clinical and in vitro, as well as clinical, data including but not limited to drugs, immunotherapy and gene therapy. It is an important source of information on the development of vaccine programs and preventative measures aimed at virus eradication.
期刊最新文献
Fixation and reversion of mutations in the receptor-binding domain of the SARS-CoV-2 spike protein: A 2020-2024 analysis. Bypassing primary antiretroviral therapy centres in Sub-Saharan Africa: An integrative review of the theoretical and empirical literature. Development of a latency model for HIV-1 subtype C and the impact of long terminal repeat element genetic variation on latency reversal. Assessing favipiravir impact on SARS-CoV-2 transmission within households: Insights from a multi-center study (FaviPrev). Hepatitis B prevalence in an endemic area of hepatitis C virus: A population-based study implicated in hepatitis elimination in Thailand.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1